Alliance between risk factors and grievousness of mucormycosis in patients suffering from COVID-19
DOI:
https://doi.org/10.18203/2320-6012.ijrms20223634Keywords:
COVID-19, Diabetes mellitus, Hypertension, Mucormycosis, Periorbital cellulitis, SteroidsAbstract
Background: Mucormycosis is a black fungal mold showing a sudden surge in covid era and left as a trail of COVID-19. It wouldn’t be wrong to say that both mucormycosis and COVID-19 prey on the immunocompromised by colonizing the nose-sinuses-orbit-eye-brain.
Methods: 30 patients of suspected ROCM were included which presented a gamut of red flags ranging from numbness and pain over the cheek to diminution of vision (DOV) and diplopia. Mucormycosis was confirmed by KOH mount and gadolinium-enhanced MRI. Ophthalmic assessment included visual acuity, IOP measurement, colour vision, extraocular movements, anterior and posterior segment evaluation using slit lamp and fundoscopy.
Results: Risk factors being diabetes mellitus (73.3%), history of oxygen supply during hospital stay (53.3%) and hypertension (53.3%). 16/30 (53.3%) had good vision: <6/6 but >6/12. 11/30 (36.7%) had impaired vision: <6/12 but >6/60. 3/30 (10%) had poor vision: <6/60. Finding being DOV: 14 (46.7%) >chemosis: 10(33.3%) >restricted EOM: 5 (16.7%) >periorbital cellulitis: 4 (13.3%) >congestion: 4 (13.3%) >proptosis: 4 (13.3%).
Conclusions: Thus, as there is a myriad of ocular manifestations, we have tried to portray the whole spectrum here. Patients with the above-mentioned risk factors must be eyed with suspicion since delay in diagnosis and appropriate management can have calamitous implications on patient survival. However, the intervention time varies depending on the various factors like availability of the resources, awareness of the patient and expertise available for diagnosis and treatment. As this disease requires a multidisciplinary approach, ophthalmic intervention should be followed by debridement of sinuses as and when required.
References
Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi. 2019;5(1):26.
Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis. 2012;54(1):S23-34.
Patel A, Kaur H, Xess I, Michael JS, Savio J, Rudramurthy S, Singh R, Shastri P, Umabala P, Sardana R, Kindo A. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 2020;26(7):944-e9.
Prakash H, Chakrabarti A. Epidemiology of Mucormycosis in India. Microorganisms. 2021;9(3):523.
Ginsberg J, Spaulding AG, Laing VO. Cerebral phycomycosis (mucormycosis) with ocular involvement. Am J Ophthalmol. 1966;62(5):900-6.
Ferry AP, Abedi S. Diagnosis and management of rhino-orbitocerebral mucormycosis (phycomycosis): a report of 16 personally observed cases. Ophthalmology. 1983;90(9):1096-104.
Spellberg B, Kontoyiannis DP, Fredricks D, Morris MI, Perfect JR, Chin-Hong PV, et al. Risk factors for mortality in patients with mucormycosis. Med Mycol. 2012;50(6):611-8.
Berk M, Fink G, Uyeda C. Rhinomucormycosis. J Am Med Assoc. 1961;177(7):511-3.
Albert DM, Lesser RL, Cykiert RC, Zakov ZN. Orbitofacial mucormycosis with unusual pathological features. Br J Ophthalmol. 1979;63(10):699-703.
Gass JD. Ocular manifestations of acute mucormycosis. Arch Ophthalmol. 1961;65(2):226-37.
Wadsworth JA. Ocular mucormycosis: report of a case. Am J Ophthalmol. 1951;34(3):405-9.
Baker RD. Mucormycosis- a new disease? J Am Med Assoc. 1957;163(10):805-8.